IFLScience on MSN19h
A Shapeshifting Protein Is Leading Alzheimer’s Disease Researchers Down A New Path
Complex problems often require creative solutions, and the increasing global burden of Alzheimer’s disease certainly ...
Neuroscience News2d
Alzheimer’s Drug Shrinks Brain Volume by Removing Amyloid Plaques
Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques rather than neuronal damage.
Brain volume loss linked to Alzheimer's treatment may be caused by amyloid plaque removal
A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led ...
News Medical on MSN3d
Alzheimer's research presents new strategy for amyloid diagnostics
The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...
STAT1mon
Early data from Roche’s Alzheimer’s therapy show it’s hitting targets
But U.S. regulators have in recent years approved similar medicines that can reduce levels of the protein, called amyloid, in patients’ brains and that in trials modestly slowed the worsening of ...
Nature5y
An amyloid-β protein assembly in the brain is linked with impaired memory
This mechanism, which involves extracellular accumulation of a 56 kDa soluble amyloid-β (Aβ ... Their results suggest that other soluble protein assemblies could also have a role in inducing ...